Table 1.
Demographic and clinical characteristics of the study population.
| Study population |
||
|---|---|---|
| No. | % | |
| Total | 717,538 | 100 |
| Sex | ||
| F | 370,813 | 51.68 |
| M | 346,725 | 48.32 |
| Age group (years) | ||
| 0–17 | 44,455 | 6.20 |
| 18–40 | 186,386 | 25.98 |
| 41–64 | 280,965 | 39.16 |
| 65–74 | 90,690 | 12.64 |
| 75–84 | 75,623 | 10.54 |
| >84 | 39,419 | 5.49 |
| Citizenship | ||
| Italian | 645,600 | 89.97 |
| Non italian | 71,938 | 10.03 |
| Comorbidities (previous two years)* | ||
| Cardiovascular diseases | 50,157 | 7.69 |
| Tumours | 93,942 | 14.41 |
| Diabetes | 50,966 | 7.82 |
| Hypertension | 63,872 | 9.79 |
| Cerebrovascular diseases | 20,417 | 3.13 |
| Parkinson | 9,729 | 1.49 |
| Dementia | 6,632 | 1.02 |
| Mental health disorders | 17,469 | 2.68 |
| Diseases of the respiratory system | 22,522 | 3.45 |
| Renal failure | 9,521 | 1.46 |
| SARS-CoV-2 infection | 4,619 | 0.64 |
| Frailty class* | ||
| Very low | 472,815 | 72.50 |
| Low | 144,401 | 22.14 |
| Medium | 22,320 | 3.42 |
| High | 11,244 | 1.72 |
| Very high | 1,365 | 0.21 |
| Type of vaccine* | ||
| ChAdOx1-S | 23,558 | 3.28 |
| Ad26 CoV2-S | 5,557 | 0.77 |
| mRNA-1273 | 260,409 | 36.30 |
| BNT162b2 | 427,943 | 59.65 |
*
Information not available for all.